Eye Care

August 1st 2025

The FDA approves aceclidine ophthalmic solution 1.44%, the first aceclidine eye drop for presbyopia, offering a new solution for millions struggling with near vision loss.

July 31st 2025

A recent study reveals Mvasi's comparable safety profile to Avastin for retinal diseases, highlighting the need for on-label biosimilars in ophthalmology.

June 6th 2025

Patients with diabetes using glucagon-like peptide-1 (GLP-1) drugs face double the risk of developing neovascular age-related macular degeneration, highlighting crucial ocular health concerns.

May 28th 2025

FDA approves acoltremon ophthalmic solution, a groundbreaking treatment for dry eye disease, enhancing natural tear production and patient quality of life.